Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Psychiatry Research and Reviews
  4. Volume 21, Issue 1
  5. Article
Volume 21, Issue 1
  • ISSN: 2666-0822
  • E-ISSN: 2666-0830

Abstract

Psychedelics are currently being examined once more as potential remedies for untreatable biological illnesses after decades of research problems. They are frequently regarded to be physically safe and do not frequently lead to dependency or addiction. The use of psychedelic substances in the treatment of mental illness and the adoption of the Substance Act of 1970 has classified psychedelic drugs as Schedule I. The major objective of this review is to highlight the prospective use of specific psychedelic medicines, such as psilocybin, LSD, MDMA, and ayahuasca, in the treatment of various psychiatric conditions, such as treatment-resistant depression, post-traumatic traumatic stress, end-of-life anxiety, and substance misuse disorders. As documented from both animal and human studies, in addition, there will be a study of the effectiveness and safety. The body of research suggests that psychedelics may one day offer revolutionary treatments for mental diseases, contrary to conventional therapy. However, given their distinctive histories and a high potential for abuse with widespread distribution, more care and effort must be given to protect their use as efficient medical treatments instead of drugs of abuse.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cprr/10.2174/0126660822258502231120074036
2025-02-01
2024-11-15

  • From This Site

    /content/journals/cprr/10.2174/0126660822258502231120074036
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. RossellS.L. MeikleS.E. WilliamsM.L. CastleD.J. Why didn’t the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder?Aust. N. Z. J. Psychiatry202357793593610.1177/00048674231172691 37139585
     [Google Scholar]
  2. HallW. FarrellM. What can we learn from the history of research on psychedelic drugs in the addictions?Addiction2021116112936293810.1111/add.15560 34382252
     [Google Scholar]
  3. SiegelA.N. MeshkatS. BenitahK. Registered clinical studies investigating psychedelic drugs for psychiatric disorders.J. Psychiatr. Res.2021139718110.1016/j.jpsychires.2021.05.019 34048997
     [Google Scholar]
  4. KaplanR.M. Humphry osmond: The psychedelic psychiatrist.IJHSSE201632349
     [Google Scholar]
  5. VollenweiderF.X. PrellerK.H. Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders.Nat. Rev. Neurosci.2020211161162410.1038/s41583‑020‑0367‑2 32929261
     [Google Scholar]
  6. NuttD. Psychedelic drugs—a new era in psychiatry?Dialogues Clin. Neurosci.201921213914710.31887/DCNS.2019.21.2/dnutt 31636488
     [Google Scholar]
  7. HalberstadtA.L. ChathaM. KleinA.K. WallachJ. BrandtS.D. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species.Neuropharmacology202016710793310.1016/j.neuropharm.2019.107933 31917152
     [Google Scholar]
  8. AdayJ.S. WoodJ.R. BloeschE.K. DavoliC.C. Psychedelic drugs and perception: A narrative review of the first era of research.Rev. Neurosci.202132555957110.1515/revneuro‑2020‑0094 33550787
     [Google Scholar]
  9. SchenbergE.E. Psychedelic drugs as new tools in psychiatric therapeutics.Br. J. Psychiatry202143212112210.1590/1516‑4446‑2020‑0012 32578688
     [Google Scholar]
  10. LordL.D. ExpertP. AtasoyS. Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin.Neuroimage201919912714210.1016/j.neuroimage.2019.05.060 31132450
     [Google Scholar]
  11. MadsenM.K. FisherP.M. BurmesterD. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels.Neuropsychopharmacology20194471328133410.1038/s41386‑019‑0324‑9 30685771
     [Google Scholar]
  12. GreenwayK.T. GarelN. JeromeL. FeducciaA.A. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.Expert Rev. Clin. Pharmacol.202013665567010.1080/17512433.2020.1772054 32478631
     [Google Scholar]
  13. KredietE. BostoenT. BreeksemaJ. Reviewing the potential of psychedelics for the treatment of PTSD.Int. J. Neuropsychopharmacol.202023638540010.1093/ijnp/pyaa018
     [Google Scholar]
  14. KangaslampiS. Uncovering psychological mechanisms mediating the effects of drugs: some issues and comments using the example of psychedelic drugs.Psychopharmacology2020237123799380210.1007/s00213‑020‑05703‑9 33151375
     [Google Scholar]
  15. GoldbergS.B. PaceB.T. NicholasC.R. RaisonC.L. HutsonP.R. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.Psychiatry Res.202028411274910.1016/j.psychres.2020.112749 31931272
     [Google Scholar]
  16. BershadA.K. PrellerK.H. LeeR. Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity.Biol. Psychiatry Cogn. Neurosci. Neuroimaging20205446146710.1016/j.bpsc.2019.12.007 32033922
     [Google Scholar]
  17. ReiffC.M. RichmanE.E. NemeroffC.B. Psychedelics and psychedelic-assisted psychotherapy.Am. J. Psychiatry2020177539141010.1176/appi.ajp.2019.19010035 32098487
     [Google Scholar]
  18. MitchellJ.M. Ot’aloraG.M. van der KolkB. MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial.Nat. Med.202329102473248010.1038/s41591‑023‑02565‑4 37709999
     [Google Scholar]
  19. González-MaesoJ. WeisstaubN.V. ZhouM. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.Neuron200753343945210.1016/j.neuron.2007.01.008 17270739
     [Google Scholar]
  20. LarkumM. A cellular mechanism for cortical associations: An organizing principle for the cerebral cortex.Trends Neurosci.201336314115110.1016/j.tins.2012.11.006 23273272
     [Google Scholar]
  21. GrobC.S. DanforthA.L. ChopraG.S. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.Arch. Gen. Psychiatry2011681717810.1001/archgenpsychiatry.2010.116 20819978
     [Google Scholar]
  22. DoblinR.E. ChristiansenM. JeromeL. BurgeB. The past and future of psychedelic science: An introduction to this issue.J. Psychoactive Drugs2019512939710.1080/02791072.2019.1606472 31132970
     [Google Scholar]
  23. Palhano-FontesF. BarretoD. OniasH. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial.Psychol. Med.201949465566310.1017/S0033291718001356 29903051
     [Google Scholar]
  24. WinterJ.C. RiceK.C. AmorosiD.J. RabinR.A. Psilocybin-induced stimulus control in the rat.Pharmacol. Biochem. Behav.200787447248010.1016/j.pbb.2007.06.003 17688928
     [Google Scholar]
  25. CarbonaroT.M. BradstreetM.P. BarrettF.S. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.J. Psychopharmacol.2016301212681278
     [Google Scholar]
  26. RosemanL. HaijenE. Idialu-IkatoK. KaelenM. WattsR. Carhart-HarrisR. Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory.J. Psychopharmacol.20193391076108710.1177/0269881119855974 31294673
     [Google Scholar]
  27. LewisC.R. PrellerK.H. KraehenmannR. MichelsL. StaempfliP. VollenweiderF.X. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.Neuroimage2017159707810.1016/j.neuroimage.2017.07.020 28711736
     [Google Scholar]
  28. LyC. GrebA.C. CameronL.P. Psychedelics promote structural and functional neural plasticity.Cell Rep.201823113170318210.1016/j.celrep.2018.05.022 29898390
     [Google Scholar]
  29. CalveyT. HowellsF.M. An introduction to psychedelic neuroscience.In: Progress in Brain Research.Elsevier B.V.201812310.1016/bs.pbr.2018.09.013
     [Google Scholar]
  30. KvamT.M. StewartL.H. AndreassenO.A. Psychedelic drugs in the treatment of anxiety, depression and addiction.Tidsskr. Nor. Laegeforen.20181381810.4045/tidsskr.17.1110
     [Google Scholar]
  31. SellersE.M. RomachM.K. LeidermanD.B. Studies with psychedelic drugs in human volunteers.Neuropharmacology201814211613410.1016/j.neuropharm.2017.11.029 29162429
     [Google Scholar]
  32. PrellerK.H. SchilbachL. PokornyT. FlemmingJ. SeifritzE. VollenweiderF.X. Role of the 5-HT2A receptor in self- and other-initiated social interaction in lysergic acid diethylamide-induced states: A pharmacological fMRI study.J. Neurosci.201838143603361110.1523/JNEUROSCI.1939‑17.2018 29555857
     [Google Scholar]
  33. StroudJ.B. FreemanT.P. LeechR. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression.Psychopharmacology2018235245946610.1007/s00213‑017‑4754‑y 29085980
     [Google Scholar]
  34. Lladó-PelfortL. CeladaP. RigaM.S. Effects of hallucinogens on neuronal activity.In: Current Topics in Behavioral Neurosciences.Springer Verlag201875105
     [Google Scholar]
  35. Carhart-HarrisR.L. GoodwinG.M. The therapeutic potential of psychedelic drugs: Past, present, and future.Neuropsychopharmacology201742112105211310.1038/npp.2017.84 28443617
     [Google Scholar]
  36. EvansJ.W. SzczepanikJ. BrutschéN. ParkL.T. NugentA.C. ZarateC.A.Jr Default mode connectivity in major depressive disorder measured up to 10 days after ketamine administration.Biol. Psychiatry201884858259010.1016/j.biopsych.2018.01.027 29580569
     [Google Scholar]
  37. MarekG.J. Interactions of hallucinogens with the glutamatergic system: Permissive network effects mediated through cortical layer V pyramidal neurons.Current Topics in Behavioral Neurosciences.Springer Verlag2018107135
     [Google Scholar]
  38. PrellerK.H. HerdenerM. PokornyT. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation.Curr. Biol.201727345145710.1016/j.cub.2016.12.030 28132813
     [Google Scholar]
  39. KraehenmannR. PokornyD. VollenweiderL. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation.Psychopharmacology2017234132031204610.1007/s00213‑017‑4610‑0 28386699
     [Google Scholar]
  40. KyzarE.J. NicholsC.D. GainetdinovR.R. NicholsD.E. KalueffA.V. Psychedelic drugs in biomedicine.Trends Pharmacol. Sci.20173811992100510.1016/j.tips.2017.08.003 28947075
     [Google Scholar]
  41. RossS. BossisA. GussJ. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial.J. Psychopharmacol.201630121165118010.1177/0269881116675512 27909164
     [Google Scholar]
  42. RuckerJ.J.H. JelenL.A. FlynnS. FrowdeK.D. YoungA.H. Psychedelics in the treatment of unipolar mood disorders: A systematic review.J. Psychopharmacol.201630121220122910.1177/0269881116679368 27856684
     [Google Scholar]
  43. BarreA. BerthouxC. De BundelD. Presynaptic serotonin 2A receptors modulate thalamocortical plasticity and associative learning.Proc. Natl. Acad. Sci.201611310E1382E139110.1073/pnas.1525586113 26903620
     [Google Scholar]
  44. BogenschutzM.P. ForcehimesA.A. PommyJ.A. WilcoxC.E. BarbosaP.C.R. StrassmanR.J. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study.J. Psychopharmacol.201529328929910.1177/0269881114565144 25586396
     [Google Scholar]
  45. JohnsonM.W. Garcia-RomeuA. CosimanoM.P. GriffithsR.R. Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction.J. Psychopharmacol.2014281198399210.1177/0269881114548296 25213996
     [Google Scholar]
  46. PokornyT. PrellerK.H. KraehenmannR. VollenweiderF.X. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.Eur. Neuropsychopharmacol.201626475676610.1016/j.euroneuro.2016.01.005 26875114
     [Google Scholar]
  47. LebedevA.V. LövdénM. RosenthalG. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin.Hum. Brain Mapp.20153631373153
     [Google Scholar]
  48. OsórioF.L. SanchesR.F. MacedoL.R. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report.Rev. Bras. Psiquiatr.2015371132010.1590/1516‑4446‑2014‑1496 25806551
     [Google Scholar]
  49. KrebsT.S. JohansenP.Ø. Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials.J. Psychopharmacol.2012267994100210.1177/0269881112439253 22406913
     [Google Scholar]
  50. GasserP. KirchnerK. PassieT. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects.J. Psychopharmacol.2015291576810.1177/0269881114555249 25389218
     [Google Scholar]
  51. BelouinS.J. HenningfieldJ.E. Psychedelics: Where we are now, why we got here, what we must do.Neuropharmacology201814271910.1016/j.neuropharm.2018.02.018 29476779
     [Google Scholar]
  52. CeladaP. PuigM.V. ArtigasF. Serotonin modulation of cortical neurons and networks.Front. Integr. Nuerosci.2013725Epub ahead of print10.3389/fnint.2013.00025 23626526
     [Google Scholar]
  53. WoodJ. KimY. MoghaddamB. Disruption of prefrontal cortex large scale neuronal activity by different classes of psychotomimetic drugs.J. Neurosci.20123293022303110.1523/JNEUROSCI.6377‑11.2012 22378875
     [Google Scholar]
  54. SaulinA. SavliM. LanzenbergerR. Serotonin and molecular neuroimaging in humans using PET.Amino Acids20124262039205710.1007/s00726‑011‑1078‑9 21947614
     [Google Scholar]
  55. QuednowB.B. KometerM. GeyerM.A. VollenweiderF.X. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.Neuropsychopharmacology201237363064010.1038/npp.2011.228 21956447
     [Google Scholar]
  56. McClure-BegleyT.D. RothB.L. The promises and perils of psychedelic pharmacology for psychiatry.Nat. Rev. Drug Discov.202221646347310.1038/s41573‑022‑00421‑7 35301459
     [Google Scholar]
  57. VollenweiderF.X. SmallridgeJ.W. Classic psychedelic drugs: Update on biological mechanisms.Pharmacopsychiatry202255312113810.1055/a‑1721‑2914 35079988
     [Google Scholar]
  58. BenneyworthM.A. SmithR.L. BarrettR.J. Sanders-BushE. Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice.Psychopharmacology2005179485486210.1007/s00213‑004‑2108‑z 15645221
     [Google Scholar]
  59. BolwigT.G. Neuroimaging and electroconvulsive therapy: A review.J. ECT201430213814210.1097/YCT.0000000000000140 24800687
     [Google Scholar]
  60. Carhart-HarrisR.L. ErritzoeD. WilliamsT. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.Proc. Natl. Acad. Sci.201210962138214310.1073/pnas.1119598109 22308440
     [Google Scholar]
  61. MithoeferM.C. WagnerM.T. MithoeferA.T. JeromeL. DoblinR. The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.J. Psychopharmacol.201125443945210.1177/0269881110378371 20643699
     [Google Scholar]
  62. McAlonanK. CavanaughJ. WurtzR.H. Guarding the gateway to cortex with attention in visual thalamus.Nature2008456722039139410.1038/nature07382 18849967
     [Google Scholar]
  63. SantosR.G. BousoJ.C. HallakJ.E.C. Ayahuasca: What mental health professionals need to know.Arch. Clin. Psychiatry201744410310910.1590/0101‑60830000000130
     [Google Scholar]
  64. de GregorioD. Aguilar-VallesA. PrellerK.H. Hallucinogens in mental health: Preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine.J. Neurosci.202141589190010.1523/JNEUROSCI.1659‑20.2020
     [Google Scholar]
  65. ZanosP. GouldT.D. Mechanisms of ketamine action as an antidepressant.Mol. Psychiatry201823480181110.1038/mp.2017.255 29532791
     [Google Scholar]
  66. VillanuevaV. GarcésM. López-GonzálezF.J. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.Epilepsy Res.201612620121010.1016/j.eplepsyres.2016.08.001 27521586
     [Google Scholar]
  67. GreiciusM.D. FloresB.H. MenonV. Resting-state functional connectivity in major depression: Abnormally increased contributions from subgenual cingulate cortex and thalamus.Biol. Psychiatry200762542943710.1016/j.biopsych.2006.09.020 17210143
     [Google Scholar]
/content/journals/cprr/10.2174/0126660822258502231120074036
Loading
Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists
Curr Psyc Res Rev 21, 2 (2025); https://doi.org/10.2174/0126660822258502231120074036
/content/journals/cprr/10.2174/0126660822258502231120074036
/content/journals/cprr/10.2174/0126660822258502231120074036
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): ayahuasca; LSD; MDMA; psilocybin; Psychedelic drugs; psychiatry; psychotherapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test